Simplify Volt RoboCar Disruption and Tech ETF (ARCA: VCAR)

Últimas noticias sobre Simplify Volt RoboCar Disruption and Tech ETF (ARCA:VCAR)

Simplify Volt RoboCar Disruption and Tech ETF

Technology

Consumer Cyclical

Financial Services

Basic Materials

Communication Services

Industrials

Healthcare

Consumer Defensive

Other

Energy

The adviser and sub-adviser seek to achieve the Funds investment objective by investing in U.S. and foreign equity securities and equity securities of companies engaging in activities that are consistent with Funds investment theme of robocar disruption and technology. The adviser applies an option overlay strategy to the Funds equity investments.

Nvidia Corp.

Advanced Micro Devices Inc.

Microsoft Corp

Tesla, Inc.

Asml Holding N.V., Ordinary Shares

Alphabet Inc-cl C

Amazon.Com Inc

Lemonade Inc

Apple Inc

Simplify Volt Robocar Disruption ETF

WIIM

SSRM

SSR Mining shares are trading lower following a Q3 earnings miss.

<p>RBC Capital  analyst Andrew Wong   maintains Ag Growth International (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AFN#TSX">AFN</a>) with a Outperform and lowers the price target from C$80 to C$75.</p>


News

Price Target

Analyst Ratings

TSX:AFN

RBC Capital Maintains Outperform on Ag Growth International, Lowers Price Target to C$75

Marriott Vacations shares are trading higher after the company reported better-than-expected Q3 financial results.

NVMI

Nova shares are trading higher after the company reported better-than-expected Q3 EPS and sales and provided Q4 revenue and EPS guidance above analyst estimates.

ANSS

Ansys shares are trading higher after the company reported Q3 EPS and sales that significantly beat analyst estimates.

Hanesbrands shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results and issued Q4 sales guidance above estimates.

WTRG

Essential Utilities shares are trading lower after Jefferies downgraded the stock from Buy to Hold and lowered the price target from $44 to $41.

Transdigm Group shares are trading lower. The company reported Q4 financial results.

<p>UBS  analyst Gavin Parsons   maintains Howmet Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) with a Neutral and raises the price target from $103 to $120.</p>


UBS Maintains Neutral on Howmet Aerospace, Raises Price Target to $120

GOLF

Acushnet Holdings shares are trading higher after the company reported better-than-expected Q3 financial results.

<p>UBS  analyst Taylor McGinnis   maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Neutral and raises the price target from $550 to $650.</p>


HUBS

UBS Maintains Neutral on HubSpot, Raises Price Target to $650

<p>UBS  analyst Jon Windham   maintains GFL Environmental (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>) with a Buy and raises the price target from $47 to $50.</p>


UBS Maintains Buy on GFL Environmental, Raises Price Target to $50

<p><strong>Airbnb, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) will release earnings results for its third quarter, after the c<a href="https://www.benzinga.com/quote/abnb/earnings">losing bell on Thursday, Nov. 7</a>.</p>
<p>Analysts expect the San Francisco, California-based bank to report quarterly earnings at $2.14 per share, down from $6.63 per share in the year-ago period. Airbnb projects to report revenue of $3.72 billion for the recent quarter, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.</p>
<p>Airbnb has completed 26 years of existence as a company, having launched on Aug. 11, 2008.</p>
<p>Airbnb shares gained 2.2% to close at $140.91 on Wednesday.</p>
<p>Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.</p>
<p>Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/ABNB/analyst-ratings">analysts have rated the company</a> in the recent period.</p>
<ul>
<li>UBS analyst Stephen Ju maintained a Neutral rating and raised the price target from $134 to $144 on Oct. 23. This analyst has an accuracy rate of 75%.</li>
<li>B of A Securities analyst Justin Post maintained a Neutral rating and raised the price target from $132 to $142 on Oct. 11. This analyst has an accuracy rate of 85%.</li>
<li>Wells Fargo analyst Ken Gawrelski maintained an Underweight rating and increase the price target from $100 to $102 on Oct. 8. This analyst has an accuracy rate of 72%.</li>
<li>Cantor Fitzgerald analyst Deepak Mathivanan reiterated an Underweight rating with a price target of $94 on Sept. 30. This analyst has an accuracy rate of 78%.</li>
<li>Mizuho analyst James Lee maintained an Outperform rating and slashed the price target from $175 to $170 on Sept. 13. This analyst has an accuracy rate of 79%.</li>
</ul>
<p>Considering buying ABNB stock? Here&#8217;s what analysts think: </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="550" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07020528/image-66-1024x550.png" alt="" class="wp-image-634523" style="width:650px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07020528/image-66-1024x550.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07020528/image-66-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07020528/image-66-768x412.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07020528/image-66.png 1231w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom">Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom</a></strong></li>
</ul>


Earnings

Markets

Trading Ideas

ABNB

Airbnb Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

<p>Lamar Advertising (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAMR#NASDAQ">LAMR</a>) will release its quarterly earnings report on Friday, 2024-11-08. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Lamar Advertising to report an <strong>earnings per share</strong> (EPS) of $1.45.</p>
<p>The announcement from Lamar Advertising is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Historical Earnings Performance</h3>
<p>The company's EPS missed by $0.04 in the last quarter, leading to a 1.0% drop in the share price on the following day.</p>
<p>Here's a look at Lamar Advertising's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.38</td>
<td>0.81</td>
<td>1.35</td>
<td>1.38</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.34</td>
<td>0.76</td>
<td>1.46</td>
<td>1.37</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-3.0%</td>
<td>-2.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730995330_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Lamar Advertising were trading at $132.14 as of November 06. Over the last 52-week period, shares are up 45.67%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Views on Lamar Advertising</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Lamar Advertising.</p>
<p>Analysts have given Lamar Advertising a total of 2 ratings, with the consensus rating being Buy. The average one-year price target is $136.0, indicating a potential 2.92% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Gaming and Leisure Props, EPR Props and Outfront Media, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>As per analysts' assessments, Gaming and Leisure Props is favoring an Outperform trajectory, with an average 1-year price target of $53.83, suggesting a potential 59.26% downside.</li>
<li>Analysts currently favor an Underperform trajectory for EPR Props, with an average 1-year price target of $48.6, suggesting a potential 63.22% downside.</li>
<li>Outfront Media is maintaining an Outperform status according to analysts, with an average 1-year price target of $20.0, indicating a potential 84.86% downside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Gaming and Leisure Props, EPR Props and Outfront Media, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lamar Advertising</td>
<td>Buy</td>
<td>4.46%</td>
<td>$381.99M</td>
<td>11.54%</td>
</tr>
<tr>
<td>Gaming and Leisure Props</td>
<td>Outperform</td>
<td>7.17%</td>
<td>$373.58M</td>
<td>4.40%</td>
</tr>
<tr>
<td>EPR Props</td>
<td>Underperform</td>
<td>-6.79%</td>
<td>$148.48M</td>
<td>1.68%</td>
</tr>
<tr>
<td>Outfront Media</td>
<td>Outperform</td>
<td>1.81%</td>
<td>$237.50M</td>
<td>29.37%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Lamar Advertising ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.</p>
<h3>All You Need to Know About Lamar Advertising</h3>
<p>Lamar Advertising Co is an outdoor advertising company organized as a real estate investment trust for U.S. federal income tax purposes. Lamar's core revenue-generating activity is leasing space for advertising on billboards, buses, shelters, benches, logo plates, and airport terminals through short-term agreements. The company is involved in this process from ad copy production to the placement and maintenance of physical advertisements. The vast majority of Lamar's revenue comes from renting ad space on its portfolio of static and digital roadside billboard displays in the U.S. The states of Pennsylvania and Texas house a proportion of these. The company's customers are restaurant, service, healthcare, and retail firms in terms of total revenue.</p>
<h3>Lamar Advertising: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Lamar Advertising displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>4.46%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Lamar Advertising's net margin is impressive, surpassing industry averages. With a net margin of <strong>24.29%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>11.54%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Lamar Advertising's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>2.09%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Lamar Advertising's debt-to-equity ratio is below the industry average. With a ratio of <b>3.88</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/LAMR/earnings"><strong>To track all earnings releases for Lamar Advertising visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


LAMR

Insights into Lamar Advertising's Upcoming Earnings

<p>Susquehanna  analyst Christopher Rolland   maintains Wolfspeed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) with a Neutral and lowers the price target from $16 to $11.</p>


WOLF

Susquehanna Maintains Neutral on Wolfspeed, Lowers Price Target to $11

<p>NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) is preparing to release its quarterly earnings on Friday, 2024-11-08. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect NRG Energy to report an <strong>earnings per share</strong> (EPS) of $2.22.</p>
<p>NRG Energy bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>The company's EPS beat by $1.78 in the last quarter, leading to a 2.98% increase in the share price on the following day.</p>
<p>Here's a look at NRG Energy's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.59</td>
<td>0.88</td>
<td>3.01</td>
<td>4.04</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>3.37</td>
<td>2.31</td>
<td>2.02</td>
<td>1.41</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>3.0%</td>
<td>1.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730995323_0.png" alt="eps graph" /></p>
<h3>NRG Energy Share Price Analysis</h3>
<p>Shares of NRG Energy were trading at $92.39 as of November 06. Over the last 52-week period, shares are up 110.47%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<h3>Analysts' Take on NRG Energy</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on NRG Energy.</p>
<p>A total of 7 analyst ratings have been received for NRG Energy, with the consensus rating being Neutral. The average one-year price target stands at $104.29, suggesting a potential 12.88% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of  and NRG Energy, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary presents essential metrics for  and NRG Energy, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRG Energy</td>
<td>Neutral</td>
<td>4.90%</td>
<td>$2.30B</td>
<td>25.66%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>NRG Energy is positioned in the middle among its peers for consensus rating. It ranks in the middle for revenue growth. The company is at the top for gross profit. NRG Energy is at the top for return on equity.</p>
<h3>All You Need to Know About NRG Energy</h3>
<p>NRG Energy is one of the largest retail energy providers in the us, with 6 million customers. Vivint Smart Home, which NRG acquired in 2023, has 2 million home services customers. NRG also is one of the largest us independent power producers, with 13 gigawatts of coal, gas, and oil power generation capacity primarily in Texas. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.</p>
<h3>Financial Insights: NRG Energy</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> NRG Energy's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>4.9%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Utilities sector.</p>
<p><strong>Net Margin:</strong> NRG Energy's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>10.83%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>25.66%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> NRG Energy's ROA excels beyond industry benchmarks, reaching <strong>2.82%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> NRG Energy's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>3.67</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<p><a href="https://www.benzinga.com/quote/NRG/earnings"><strong>To track all earnings releases for NRG Energy visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


NRG Energy's Earnings: A Preview

<p>TELUS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TU#NYSE">TU</a>) is preparing to release its quarterly earnings on Friday, 2024-11-08. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect TELUS to report an <strong>earnings per share</strong> (EPS) of $0.18.</p>
<p>The market awaits TELUS's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.02, which was followed by a 0.0% drop in the share price the next day.</p>
<p>Here's a look at TELUS's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.16</td>
<td>0.170</td>
<td>0.170</td>
<td>0.240</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.18</td>
<td>0.192</td>
<td>0.176</td>
<td>0.186</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>-2.0%</td>
<td>3.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730995313_0.png" alt="eps graph" /></p>
<h3>TELUS Share Price Analysis</h3>
<p>Shares of TELUS were trading at $15.11 as of November 06. Over the last 52-week period, shares are down 12.1%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/TU/earnings"><strong>To track all earnings releases for TELUS visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Uncovering Potential: TELUS's Earnings Preview

<p>5 analysts have expressed a variety of opinions on Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Ionis Pharmaceuticals and provided 12-month price targets. The average target is $65.4, accompanied by a high estimate of $77.00 and a low estimate of $55.00. Highlighting a 1.51% decrease, the current average has fallen from the previous average price target of $66.40. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730995312_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Ionis Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$77.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ionis Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ionis Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Ionis Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Ionis Pharmaceuticals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/IONS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Ionis Pharmaceuticals analyst ratings.</strong></a></p>
<h2>Get to Know Ionis Pharmaceuticals Better</h2>
<p>Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.</p>
<h3>Ionis Pharmaceuticals: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Ionis Pharmaceuticals showcased positive performance, achieving a revenue growth rate of <strong>19.55%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Ionis Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-29.42%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Ionis Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-23.66%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-2.43%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Ionis Pharmaceuticals's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>5.47</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


IONS

A Glimpse Into The Expert Outlook On Ionis Pharmaceuticals Through 5 Analysts

<p>9 analysts have expressed a variety of opinions on Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $80.89, along with a high estimate of $95.00 and a low estimate of $64.00. Observing a 10.81% increase, the current average has risen from the previous average price target of $73.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730995304_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A comprehensive examination of how financial experts perceive Johnson Controls Intl is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Brett Linzey</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Joe O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$64.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Noah Kaye</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Andrew Obin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Andrew Obin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Chris Snyder</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$85.00</td>
<td>-</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$69.00</td>
<td>$61.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Johnson Controls Intl. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Johnson Controls Intl compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Johnson Controls Intl's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Johnson Controls Intl's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/JCI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Johnson Controls Intl analyst ratings.</strong></a></p>
<h2>Get to Know Johnson Controls Intl Better</h2>
<p>Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration units, and fire and security solutions. Commercial HVAC accounts for over 45% of sales, fire and security represents roughly 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 15% of revenue. In fiscal 2023, Johnson Controls generated nearly $27 billion in revenue.</p>
<h3>Johnson Controls Intl's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Johnson Controls Intl's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>1.37%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Johnson Controls Intl's net margin is impressive, surpassing industry averages. With a net margin of <strong>13.48%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>6.17%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Johnson Controls Intl's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>2.25%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Johnson Controls Intl's debt-to-equity ratio is below the industry average. With a ratio of <b>0.65</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Glimpse Into The Expert Outlook On Johnson Controls Intl Through 9 Analysts

<p>Deep-pocketed investors have adopted a bullish approach towards Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HIMS usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Hims &amp; Hers Health. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 60% leaning bullish and 30% bearish. Among these notable options, 3 are puts, totaling $130,350, and 7 are calls, amounting to $304,590.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $35.0 for Hims &amp; Hers Health during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Hims &amp; Hers Health stands at 1738.22, with a total volume reaching 1,550.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Hims &amp; Hers Health, situated within the strike price corridor from $15.0 to $35.0, throughout the last 30 days.</p>
<h3>Hims &amp; Hers Health Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730995296_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.0</td>
<td>$1.85</td>
<td>$1.95</td>
<td>$25.00</td>
<td>$58.5K</td>
<td>146</td>
<td align="right">303</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$8.4</td>
<td>$8.2</td>
<td>$8.3</td>
<td>$20.00</td>
<td>$58.1K</td>
<td>3.5K</td>
<td align="right">172</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$5.9</td>
<td>$5.7</td>
<td>$5.9</td>
<td>$24.00</td>
<td>$46.6K</td>
<td>124</td>
<td align="right">81</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$5.9</td>
<td>$5.8</td>
<td>$5.8</td>
<td>$24.00</td>
<td>$45.8K</td>
<td>124</td>
<td align="right">160</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$11.5</td>
<td>$11.3</td>
<td>$11.38</td>
<td>$15.00</td>
<td>$45.5K</td>
<td>907</td>
<td align="right">48</td>
</tr>
</tbody>
</table>
</p>
<h3>About Hims &amp; Hers Health</h3>
<p>Hims &amp; Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.</p>
<p>In light of the recent options history for Hims &amp; Hers Health, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Hims &amp; Hers Health</h3>
<ul>
<li>Trading volume stands at 4,521,358, with HIMS's price up by 0.17%, positioned at $23.46.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 109 days.</li>
</ul>
<h3>Professional Analyst Ratings for Hims &amp; Hers Health</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $24.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from Piper Sandler downgraded its rating to Neutral, setting a price target of $21.<br />
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for Hims &amp; Hers Health, targeting a price of $25.<br />
&#x2A; An analyst from B of A Securities persists with their Buy rating on Hims &amp; Hers Health, maintaining a target price of $23.<br />
&#x2A; Maintaining their stance, an analyst from Deutsche Bank continues to hold a Hold rating for Hims &amp; Hers Health, targeting a price of $27.<br />
&#x2A; An analyst from Canaccord Genuity has decided to maintain their Buy rating on Hims &amp; Hers Health, which currently sits at a price target of $28. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Hims &amp; Hers Health options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Smart Money Is Betting Big In HIMS Options

China Goes Big And Fuels More Stock Market Gains; The S&P 500 Has Only Done This 7 Times Before

Can Big Tech's AI Ambitions Continue To Drive Markets Higher?

Q4 2024 Equity Market Outlook

16 Years In Global Equity Markets Since The Global Financial Crisis

Thematic Investing: More Than Just A Good Story

Countdown To Election Day: The Policies That Will Matter To Markets

'Frighteningly' Great Markets This Past Year Make History - Going Forward Should We Be 'Scared'?

Harris Or Trump? How The Next President Could Change The Game For Stocks, Taxes, And Inflation

Comments

Simplify Volt RoboCar Disruption and Tech ETF

Noticias

Últimas noticias sobre Simplify Volt RoboCar Disruption and Tech ETF (ARCA:VCAR)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL